London close: FTSE falls on dollar dip, ex-divs and tendency to gold safety
16th Feb 2017 17:00
(ShareCast News) - London equities limped to a lower close Thursday, pulled down by a trinity of factors including dollar weakness, a tendency to safe-haven gold and ex-dividend stocks. These combined to see the FTSE 100 down 0.34% to 7,277.92, and the FTSE 250 down -0.65%% to 18,705.72. Both ladder
Read moreAstraZeneca partner Valeant gets US FDA approval for Siliq injection
16th Feb 2017 14:42
(ShareCast News) - AstraZeneca's partner Valeant Pharmaceuticals has received approval from the US Food and Drug Administration for the Siliq injection to treat adult patients with moderate-to-severe plaque psoriasis. The pharmaceuticals giant has given Valeant the exclusive license to develop and c
Read moreAstrazeneca still a 'buy' after profit warning, says Deutsche Bank
6th Feb 2017 10:17
(ShareCast News) - Deutsche Bank has reiterated a 'buy' rating on Astrazeneca but cut the target price to 5,500p from 6,000p after the drug maker warned that profit and revenue would fall this year. Last Thursday Astrazeneca issued a profit warning as cheaper generic versions of its cholesterol drug
Read moreLondon open: FTSE gains ahead of BoE, Brexit White Paper
2nd Feb 2017 08:31
(ShareCast News) - London stocks were slightly higher in early trading on Super Thursday, as investors awaited a rate decision from the Bank of England, the Inflation Report and minutes together with the government's White Paper on Brexit. As of 0835 GMT the FTSE 100 was up 0.21% or 15.05 points at
Read moreAstraZeneca sales shrink but future hangs on drug pipeline
2nd Feb 2017 08:08
(ShareCast News) - AstraZeneca reported a second interim dividend after posting flat core earnings for 2016 after a 13% decline in revenues in the fourth quarter, but the company and investors are holding their breath in hope that 2017 will be "a defining year" for a dozen potential blockbuster drug
Read moreSector movers: Cyclicals bounce back, Evraz in the lead
1st Feb 2017 15:46
(ShareCast News) - There was a clear split in the market on Wednesday as cyclicals bounced back and the more defensive segments of the market were relegated to the bottom of the pile. Thus, shares in Prudential and Aviva were to be seen pacing gains among life insurers as yields on benchmark 10-year
Read moreMonday broker round-up
30th Jan 2017 13:05
(ShareCast News) - BT: Barclays reiterates overweight with a target price of 475p. ITV: Jefferies reiterates buy, 230p target. Phoenix: Deutsche Bank restarts coverage at buy with a 835p target. Paragon Group: JP Morgan reiterates underweight with a 355p target. Inmarsat: Deutsche Bank reiterates
Read moreFTSE 100 movers: Tesco gains while Sainsbury's loses out
27th Jan 2017 15:38
(ShareCast News) - The FTSE 100 index rose 0.17% to 7,173.75 in the late afternoon. Supermarket giant Tesco climbed as it announced it has agreed to merge with the UK's largest food wholesale operator Booker Group. Under the terms of the merger, each Booker scheme shareholder would receive 0.861 new
Read moreFDA grants AstraZeneca six months paediatric exclusivity for Symbicort
26th Jan 2017 11:24
(ShareCast News) - The US Food and Drug Administration has granted AstraZeneca six months of paediatric exclusivity for its Symbicort inhalation aerosol for asthma. The decision was based on the evaluation of trials conducted in children with asthma aged six up to 12 years in response to a written r
Read moreSector movers: BT, Smurfit Kappa move higher after hiking prices
20th Jan 2017 15:53
(ShareCast News) - Cyclicals led gains, spearheaded by oil service and general industrial issues, alongside an advance in stock of BT Group after the UK telecoms incumbent let it be known it would be raising prices for its broadband and landline services. AMEC Foster and Petrofac were up as crude oi
Read moreGlaxoSmithKline nabs Astra's Luke Miels to head global pharma
19th Jan 2017 10:20
(ShareCast News) - The president of GlaxoSmithKline's global pharmaceuticals division, Abbas Hussain, is leaving the company later this year, to be replaced by AstraZeneca's Luke Miels. Miels, who is currently executive vice president of Astra's European business, will report to current chief execut
Read moreAstraZeneca 'enhances options' in immuno-oncology trials for NSCLC
17th Jan 2017 08:24
(ShareCast News) - AstraZeneca has rejigged the target of clinical trials for its immuno-oncology treatment for non-small cell lung cancer after "strong efficacy" of its durvalumab drug shown in recent internal and external data as well as "significant opportunities in the competitive landscape". Th
Read moreSunday newspaper round-up: Hard Brexit, Putin, Hammond
15th Jan 2017 16:35
(ShareCast News) - Theresa May will announce that Britain is seeking a clean and hard Brexit in a speech this week that will promise to create a "strong new partnership" with the European Union. The prime minister will finally lay her cards on the table, making clear that the UK is set to pull out o
Read moreWednesday broker round-up
11th Jan 2017 13:32
(ShareCast News) - Burberry: Barclays upgrades to Overweight and lifts target price from 1450p to 1760p. AstraZeneca: UBS maintains Buy, keeps target price of 5,000p. Spectris: Bank of America Merill Lynch upgrades to Buy with a target price of 2600p. Unilever Plc: UBS maintains Buy with a target
Read moreAstraZeneca completes sale of rights to Pfizer
23rd Dec 2016 07:06
(ShareCast News) - AstraZeneca announced on Friday that it has completed the agreement with Pfizer for the sale of the commercialisation and development rights to its late-stage small molecule antibiotics business, comprising the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CX
Read more